Digest Network How does it work
Network
/
Society
Te
Not verified

Teva Pharmaceutical Industries Ltd

What we write about

FinanceManagementMedical Health WellnessPharmaceuticalsWant ads

116 Press releases

View all press releases
19/08/2026
Pharmaceuticals
Medical Health Wellness
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
11/08/2026
Pharmaceuticals
Want ads
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
29/07/2026
Pharmaceuticals
Management
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
09/07/2026
Pharmaceuticals
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
07/07/2026
Pharmaceuticals
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
18/06/2026
Pharmaceuticals
Want ads
Teva Releases Q2 2026 Aide Memoire
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
18/06/2026
Pharmaceuticals
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
18/06/2026
Pharmaceuticals
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
10/06/2026
Pharmaceuticals
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
08/06/2026
Pharmaceuticals
Medical Health Wellness
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0